University Of Skane
- Address
- lock Available on a paid plan
Hemic and Lymphatic Diseases
The research at University Of Skane includes studies in hemic and lymphatic diseases focused on hemophilia A and multiple myeloma. These trials are designed to evaluate new treatment approaches, improve disease control, and compare strategies that may lead to better long-term outcomes for patients.
- Testing a new gene-based therapy approach for hemophilia A
- Comparing treatment strategies for newly diagnosed multiple myeloma
This work reflects a strong interest in advancing care for blood-related cancers and inherited bleeding disorders through more effective therapies.
Immune System Diseases
Clinical trials in immune system diseases at the Department of Respiratory Medicine are centered on giant cell arteritis and generalized myasthenia gravis. The studies aim to assess safety, tolerability, and treatment effectiveness, helping identify options that may better control inflammation and immune-driven symptoms.
- Evaluating a treatment for giant cell arteritis
- Assessing safety and tolerability in generalized myasthenia gravis
These trials support efforts to improve outcomes in autoimmune conditions where managing immune activity is central to patient care.
Neoplasms
Research in neoplasms includes studies of stage III colorectal cancer and multiple myeloma. The focus is on personalizing treatment, improving survival, and testing whether different therapy choices can better match the needs of individual patients.
- Personalizing post-surgery treatment for stage III colorectal cancer
- Comparing treatment pathways in multiple myeloma
At University Of Skane, this area highlights efforts to refine cancer care using approaches that may improve effectiveness while reducing unnecessary treatment burden.
Nervous System Diseases
The site is also active in nervous system diseases, particularly amyotrophic lateral sclerosis. These trials are exploring new therapies and evaluating whether they can slow progression, preserve function, and improve quality of life for people living with this serious neurological condition.
- Studying potential treatments for amyotrophic lateral sclerosis
- Assessing functional outcomes and disease control in ALS
This research area shows a clear emphasis on finding better options for neurodegenerative disease management.
Respiratory Tract Diseases
Clinical research in respiratory tract diseases includes studies of congenital alpha-1 antitrypsin deficiency and related airflow limitation. The trials are aimed at testing inhaled treatment approaches, improving lung function, and understanding whether new therapies can help patients breathe more easily over time.
- Evaluating a new inhaled therapy for alpha-1 antitrypsin deficiency
- Measuring changes in lung function in chronic respiratory disease
With its focus on chronic lung conditions, this work supports better treatment development for patients with long-term respiratory impairment.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 of 8 therapeutic areas and 15 of 36 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 5 by active trials.
- 1Steno Diabetes Center Copenhagen2active
lock +4 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1AstraZeneca AB3trials
lock +2 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 188 other sites in Sweden
Therapeutic Area Benchmark — Sweden
Select a therapeutic area to compare against other sites in Sweden.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Sweden
Market Share
Country: Sweden
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in University Of Skane
lock Showing 1 of 16 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase III, Multicentre, Randomised, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Extension Study to Evaluate the Long-term Efficacy and Safety of Tozorakimab in Participants with Chronic Obstructive Pulmonary Disease (COPD) with a History of Exacerbations (PROSPERO) | AstraZeneca AB | Phase III | Not Recruiting | Apr 2023 | May 2026 |
IMP list
lock Showing 1 of 36 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Finerenone | 2 | Unknown | 2025-06-20 | 2025-06-20 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.